Former England captain Lewis Moody said he had been "brought in off the bench" as he paid tribute to fellow rugby players ...

The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...

The 2025 Research Innovation Grants are supporting projects focused on biomarkers, risk factors, and treatments for ALS.

The FDA approved the intrathecal gene therapy onasemnogene abeparvovec (Itvisma) to treat spinal muscular atrophy (SMA) in ...

This valuable study addresses a critical and timely question regarding the role of a subpopulation of cortical interneurons (Chrna2-expressing Martinotti cells) in motor learning and cortical dynamics ...

Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...

MIT researchers discovered that the prefrontal cortex doesn’t just send generic control signals—it tailors its messages to ...

Vision shapes behavior, and a new study by MIT neuroscientists finds behavior and internal states shape vision. The research, ...

Onasemnogene abeparvovec-brve is the first gene replacement therapy approved for SMA patients aged 2 years and older, expanding access beyond infants. Phase 3 trials demonstrated significant motor ...

Researchers in Australia have identified a three-drug combination that greatly extends the survival of motor neuron cells in ...

Novartis ( NVS) on Monday said that the U.S. FDA has approved Itvisma for the treatment of children two years and older, ...

Having raised $125 million, the Cochlear-based Epiminder lists next Monday on the back of its groundbreaking epilepsy ...